Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH0I9N)

• Drug Name: YW327.6S2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Preclinical	[1]
Non-small-cell lung cancer	2C25.Y	Preclinical	[1]

• Cross-matching ID: TTD Drug ID: DMH0I9N

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase UFO (AXL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[2]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[4]
Bemcentinib	DM0YCPL	Myelodysplastic syndrome	2A37	Phase 2	[5]
BGB-324	DMDI43Y	Breast cancer	2C60-2C65	Phase 2	[6]
Mecbotamab vedotin	DMU5KH4	Ovarian cancer	2C73	Phase 2	[7]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[2]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[8]
TP-0903	DMHTG8P	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[2]
Enapotamab vedotin	DM1PQJO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase UFO (AXL)	TTZPY6J	UFO_HUMAN	Not Available	[1]

References

• [1] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Company report (Mirati Therapeutics: formerly MethylGene)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
• [7] Clinical pipeline report, company report or official report of BioAtla
• [8] Clinical pipeline report, company report or official report of Ono Pharmaceutical.
• [9] Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.